Beauty-Stem Biomedical’s Medical Seminar Unveils Remarkable Link Between CD34 Stem Cells and Human Well-Being: Regeneration, Immune Enhancement and Hematopoiesis
LOS ANGELES, CA / ACCESSWIRE / July 28, 2023 / Ryan Huang, CEO of Beauty-Stem Biomedical, and Dr. David Chen, director of Diagnostic Medical Group of Southern California, delivered a compelling presentation highlighting the numerous benefits of CD34 stem cells. Together, they introduced the concept of “Health Deposit” to the public, emphasizing the critical importance of maintaining optimal CD34 stem cell counts for overall health and well-being.
“CD34 stem cells can be aptly described as the deposit of a Health Saving Account, where the principle is simple: the more CD34 stem cells an individual possesses, the greater their physical well-being,” said Ryan Huang, CEO of Beauty-Stem Biomedical.
Dr. David Chen has listed three major contributions of CD34 Stem cells to human well-being. “Countless clinical data and publish has proved that maintaining higher levels of CD34 stem cells can have significant health benefits.”
Beauty-Stem Biomedical encourages individuals to quantitate their own “Health Deposit” by testing their CD34 stem cell counts. Knowing the levels of these powerful cells can provide valuable insights into overall health and well-being, empowering proactive measures to boost immune function.
Contact Information
Ryan Huang
CEO
service.us@beauty-stem.com
888-341-7505
Kaihsiang Lee
Marketing Manger
service.us@beauty-stem.com
888-341-7505
SOURCE: Beauty-Stem Biomedical US
View source version on accesswire.com:
https://www.accesswire.com/770512/Beauty-Stem-Biomedical-Holds-Successful-CD34-Stem-Cell-Medical-Symposium-Exploring-Regenerative-Trend-CD34-Health-Deposit
NEW YORK, July 4, 2024 /PRNewswire/ -- The global breast tissue expander market size is estimated to…
CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free…
ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…